Novartis
Endo says Opana ER supply disruption will be temporary
February 28, 2012Manufacturing and Production Endo, Novartis, Opana ER
Endo Pharmaceuticals has said that current supply restrictions for its new Opana ER formulation of oxymorphone are likely to be …
Shortages likely as Sandoz’s Canadian plant woes continue
February 20, 2012Manufacturing and Production FDA, Novartis, Sandoz
Ongoing compliance problems at a plant in Canada operated by Novartis’ generics subsidiary Sandoz look set to cause supply disruptions …
Alnylam cuts workforce by a third
January 23, 2012Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …
Novartis’ Signifor recommended in Europe
January 20, 2012Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor
A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …
EMA to review safety of MS drug Gilenya
January 20, 2012Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya
The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …
Novartis starts late-stage biosimilar trials for Amgen drugs
January 19, 2012Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis
Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …
Lucentis approved in China
January 18, 2012Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …
Novartis reverses plant closure decision
January 18, 2012Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts
Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …
NICE says yes to Tasigna for resistant disease
January 13, 2012Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna
NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …
Novartis to cut 2,000 US jobs
January 13, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Diovan, Novartis, job cuts
Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …
Novartis recalls products as GMP issues close OTC facility
January 9, 2012Manufacturing and Production FDA, Novartis, OTC
Novartis has revealed that it is temporarily shutting down a manufacturing facility in Nebraska, US, and recalling four products as …
FDA to probe Gilenya patient death
December 21, 2011Sales and Marketing FDA, Novartis, gilenya
The FDA is investigating Novartis’s new multiple sclerosis treatment Gilenya after a patient died within hours of taking the drug. …
Novartis opens cell-based flu vaccine plant in US
December 15, 2011Manufacturing and Production Novartis, celll-based, vaccines
Novartis has officially started production at a first-of-its kind cell-based manufacturing facility for influenza vaccines in North Carolina, US. The …
Novartis warned over standards at generics sites
December 9, 2011Manufacturing and Production CGMP Failures, FDA compliance, Novartis, Sandoz
The FDA has warned Novartis that three North American production facilities operated by its generics subsidiary Sandoz are failing to …
NICE recommends two Novartis cancer treatments
December 6, 2011Sales and Marketing Glivec, Novartis, Sprycel, Tasigna
Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …
Latest content
FibroFind appoints Lee Borthwick as CEO
